Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study

By Braunig Peter   Sacchetti Emilio   Medori Rossella  

International Journal of Psychiatry in Clinical Practice, Vol. 12, Iss. 1, 2008-01 ,pp. : 74-77

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results

By Viala Annie   Cornic Francoise   Benamor Cyrine   Baldacci Chantal   Cheref Smail   Gauillard Jacques   Martin Pascal   Caroli Francois   Vacheron Marie Noëlle  

International Journal of Psychiatry in Clinical Practice, Vol. 13, Iss. 2, 2009-06 ,pp. : 138-146

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

By Ott Brian   Blake Lesley   Kagan Ethel   Resnick Malca  

Journal of Neurology, Vol. 254, Iss. 3, 2007-03 ,pp. : 351-358

Springer Publishing Company

Access to resources Recommend Favorite

Experience with risperidone long-acting injection: results of a naturalistic observation study

By Deslandes Paul   Thomas Arwel   Faulconbridge Gwawr   Davies Wendy  

International Journal of Psychiatry in Clinical Practice, Vol. 11, Iss. 3, 2007-01 ,pp. : 207-211

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study

By Bloc'h Yves Le   Baumann Pierre   Stigler Michael   Eap Chin B.   Zullino Daniele F.  

International Journal of Psychiatry in Clinical Practice, Vol. 11, Iss. 2, 2007-01 ,pp. : 123-128

Ashgate Publishing Ltd

Access to resources Recommend Favorite